Sequence information
Variant position: 304 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 468 The length of the canonical sequence.
Location on the sequence:
VTELTEFAKAIPGFANLDLN
D QVTLLKYGVYEAIFAMLSSV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VTELTEFAKAIPGFANLDLND QVTLLKYGVYEAIFAMLSSV
VTELTEFAKSIPGFANLDLND QVTLLKYGVYEAIFAMLSSV
Mouse VTELTEFAKAIPGFANLDLND QVTLLKYGVYEAIFTMLSSL
Rat VTELTEFAKAIPGFANLDLND QVTLLKYGVYEAIFTMLSSL
Xenopus laevis VTELTEFAKSIPGFTELDLND QVTLLKYGVYEAMFAMLASV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 468
Peroxisome proliferator-activated receptor alpha
Domain
239 – 466
NR LBD
Region
304 – 433
Required for heterodimerization with RXRA
Binding site
314 – 314
Synthetic agonist
Alternative sequence
175 – 468
Missing. In isoform 2.
Mutagenesis
304 – 304
D -> A. Reduced heterodimerization with RXRA. Reduced DNA binding.
Helix
302 – 321
Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.